Compare · HAYW vs TMO
HAYW vs TMO
Side-by-side comparison of Hayward Holdings Inc. (HAYW) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAYW and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $197.88B, about 63.5x HAYW ($3.12B).
- Over the past year, HAYW is down 2.0% and TMO is up 28.1% - TMO leads by 30.2 points.
- TMO has been more active in the news (9 items in the past 4 weeks vs 3 for HAYW).
- TMO has more recent analyst coverage (25 ratings vs 21 for HAYW).
- Company
- Hayward Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $14.37-3.62%
- $532.16-2.05%
- Market cap
- $3.12B
- $197.88B
- 1M return
- -2.91%
- +12.59%
- 1Y return
- -2.04%
- +28.12%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 9
- Recent ratings
- 21
- 25
Hayward Holdings Inc.
Hayward Holdings, Inc. operates as a designer, manufacturer, and marketer of various pool equipment and associated automation systems. The company offers a range of pool equipment, including pumps, filters, heaters, automatic cleaners, sanitizers, controls, and LED lights, as well as industrial thermoplastic valves and process liquid control products for in-ground residential pools, above ground pools, and commercial pools. Hayward Holdings, Inc. is based in Berkeley Heights, New Jersey.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest HAYW
- Hayward Holdings Announces Second Quarter 2026 Earnings Release and Conference Call Date
- President and CEO Holleran Kevin exercised 170,000 shares at a strike of $1.40 and sold $2,927,594 worth of shares (170,000 units at $17.22) as part of a pre-agreed trading plan (SEC Form 4)
- Hayward Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SVP, CLO, Corporate Secretary Canning Susan M. was granted 71,074 shares, increasing direct ownership by 68% to 174,911 units (SEC Form 4)
- President and CEO Holleran Kevin exercised 52,389 shares at a strike of $1.40 and sold $722,366 worth of shares (52,389 units at $13.79) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ward Edward D was granted 10,608 shares, increasing direct ownership by 27% to 50,055 units (SEC Form 4)
- Director Silber Lawrence Harris was granted 10,608 shares, increasing direct ownership by 19% to 67,407 units (SEC Form 4)
- Director Brown Kevin D. was granted 10,608 shares, increasing direct ownership by 0.33% to 3,221,432 units (SEC Form 4)
- Director Keating Ronald C was granted 10,608 shares, increasing direct ownership by 22% to 59,171 units (SEC Form 4)
- Director Soucy Arthur L was granted 10,608 shares, increasing direct ownership by 21% to 60,075 units (SEC Form 4)
Latest TMO
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- Bernstein resumed coverage on Thermo Fisher with a new price target
- SEC Form 11-K filed by Thermo Fisher Scientific Inc
- Piper Sandler initiated coverage on Thermo Fisher with a new price target